Similar investigations have also revealed that EIF3M exhibits overexpression in prostate cancer and triple-negative breast cancer, with cellular experiments confirming significant growth inhibition in tumor cells following EIF3M knockdown (Guo et al., 2024; Han et al., 2020). Here, EIF3M is linked to prostate cancer.